Pulmocide
Signal active
Organization
Contact Information
Overview
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.
About
Industries
Biotechnology, Health Care, Medical, Medical Device, Health Diagnostics
Founded
2013
Employees
11-50
Headquarters locations
London, England, United Kingdom, Europe
Social
Profile Resume
Pulmocide headquartered in Europe, operates in the Biotechnology, Health Care, Medical, Medical Device, Health Diagnostics sector. The company focuses on Biotechnology and has secured $20.5B in funding across 100 round(s). With a team of 11-50 employees, Pulmocide is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Pulmocide, raised $27.6M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
4
Lead Investors
0
Total Funding Amount
$205.5M
Details
4
Pulmocide has raised a total of $205.5M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2017 | Early Stage Venture | 30.4M | ||
| 2021 | Late Stage Venture | 92.0M | ||
| 2022 | Late Stage Venture | 52.0M | ||
| 2013 | Early Stage Venture | 27.6M |
Investors
Pulmocide is funded by 45 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Imperial Innovations | - | FUNDING ROUND - Imperial Innovations | 27.6M |
| Johnson & Johnson Development Corporation | - | FUNDING ROUND - Johnson & Johnson Development Corporation | 27.6M |
| Pulmocide | - | FUNDING ROUND - Pulmocide | 27.6M |
| F-Prime Capital | - | FUNDING ROUND - F-Prime Capital | 27.6M |
Recent Activity
News
Apr 17, 2024
Fierce Biotech - Pulmocide exits OPERA with evidence of antifungal efficacy
News
Apr 17, 2024
GlobeNewswire - Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
News
Apr 15, 2024
Fierce Biotech - Pulmocide exits OPERA with evidence of antifungal efficacy
News
Apr 15, 2024
Yahoo Finance - Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
News
Apr 15, 2024
FierceBiotech - Pulmocide exits OPERA with phase 2 evidence of antifungal safety and efficacy
Funding Round
Dec 06, 2022
Pulmocide raised $52000000 on 2022-12-06 in Series C